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Abstract: Selected molybdenum sulfur compounds with the formulas 
(M)[Mo2O2S4L] where (Et4N)2(1), L = S42-, (Et4N)(2), L = Cp, (3), L = DMF, 
K(5), L = serine, and [Mo2O2S2L2] where Na2(4), L = cysteine, and (6), L = 
threonine, were prepared and subjected to cytotoxicity studies in vitro. The 
results were analyzed to rank the compounds according to their relative 
cytotoxicity and to correlate the observed toxicity to specific composition. 
The results guide future efforts to synthesize highly water soluble, non-toxic, 
compounds. Strong correlation was observed between toxicity and cation 
selection, as well as selection of biocompatible ligands combined with alkali 
metal salts. The most toxic compound analyzed showed about 50 times less 
cytotoxicity than the cisplatin reference compound in HT-29 cells. 







Cyanide is formed as an endogenous molecule that participates in nerve 
regeneration in vivo.1 Although it is metabolized by the rhodanase enzyme it 
is highly toxic at elevated concentrations due to it’s function as a cytochrome 
c oxidase inhibitor. HCN also forms in incomplete combustion of nitrogen 
containing materials and cyanide poisoning has received increasing attention 
as a toxin in inhalation injuries from fire smoke in recent years.2 A general 
review of currently available cyanide poisoning treatments shows a gap in 
available emergency treatments.3 The need for a novel, easily handled, and 
rapidly administratable cyanide poisoning treatment calls for a highly 
efficient approach due to the acute toxicity of cyanide. Molybdenum’s role in 
biology as the active metal center in xanthine oxidase as an oxo-transfer 
agent, and in sulfite oxidase where it catalyzes the transformation of sulfite to 
sulfate, is well documented.4,5,6 Model studies of xanthine oxidase resulted in 
many interesting molecules that may have alternate function as catalysts.7,8,9 
Catalytic activity of many molybdenum sulfur compounds has been 
demonstrated for sulfur removal in hydrodesulfurization processes.10 
The catalytic sites of molybdenum enzymes possess molybdenum oxo and 
sulfido moieties. Related compounds are potentially non-toxic and may have 
biomedical applications. Examples of nanomaterials under recent study 
include covalently bonded extended solids such as MoO3, and MoS2. 
Nanoplates of molybdenum trioxide, MoO3 were shown to be non-toxic to 
HaCaT cells, and to exhibit cytotoxicity towards iMCF-7 cancer cells 
appearing promising for future cancer therapies.11 Molybdenum disulfide, 
MoS2 was explored as a photocatalyst and as an antibacterial agent.12 The 
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reductive ability of MoS2 was shown to cause increased formation of reactive 
oxygen species (ROS) in the mechanism of action related to its antibacterial 
activity. Its cytotoxicity was explored towards epithelial cells in the context 
of future applications in consumer products.13 
Tetrathiomolybdate, MoS42-, is an effective therapeutic agent aginst Wilson´s 
disease.14 The compound is remarkably well tolerated by humans showing 
very low toxicity.15 As the ammonium salt this coordination compound is 
highly soluble in water. It is air sensitive and breaks down in vivo to form 
molybdenum oxo, and sulfido compounds.7 It was shown that although 
molybdenum supplements may cause copper deficiency in animals, 16 
tetrathiomolybdate prevents this condition.17 
The Mo(IV)S2 metal chalcogenide is employed as dispersion due to its low 
aqueous solubility. It’s biological activity stems from formation of different 
oxo/sulfido compounds in vivo where the MoS2 is oxidized.7 Conversely, 
Mo(VI)O3 has high oxidation state and its reaction chemistry in vivo and in 
water is characterized by hydrolysis and reduction of the molybdenum.18 
Redox chemistry of MoOSLn mononuclear compounds is deactivated by 
dimerization to form Mo(V) dimers18 such as presented here with a very 
robust “Mo2O2S2” core structure resistant to redox chemistry at acidic and 
neutral pH.19  
Organometallic anticancer drugs and development of catalytic drugs place 
cytotoxicity and physical properties such as water solubility of the potential 
drugs at the forefront of challenges to overcome.20,21 The idea of catalysis in 
vivo is very attractive since it implies less quantity of a drug is required and 
that the drug is specific.22 The reaction of thiosulfate and cyanide is one of 
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the current cyanide poisoning treatments where thiosulfate acts as a sulfur 
donor to the rhodanase enzyme in vivo.23 Water soluble molybdenum sulfur 
complexes have potential application as catalysts for the reaction of 
thiosulfate and cyanide to form thiocyanate and sulfite in vitro.2 Dimeric 
molybdenyl complexes with bridging sulfur atoms are air stable and the 
[Mo2O2S2]2+ (Figure 1) aqua ion is stable, even under acidic conditions.19  
We synthesized novel complexes with the [Mo2O2S2]2+ core, and 
biocompatible ligands. Compounds that represent bidentate monoanionic, 
tridentate dianionic, organometallic, and neutral monodentate ligands were 
synthesized, and the known complexes (1-4) were included. The water 
solubility of the compounds was obtained colorimetrically, the cytotoxicty in 
three different cell lines was studied, and IC50 values were calculated based 
on cell viability data for the compounds in MCF-7 (breast cancer) cells, PT45 
(pancreatic cancer) cells, and HT29 (colon cancer) cells. Preliminary toxicity 
of three of these compounds in vivo is discussed in context of the results 
obtained in vitro. 
2. Experimental Section 
2.1. Reagents. Ammonium molybdate, sodium molybdate, ammonium 
sulfide, sulfur, sodium sulfide nonahydrate, cysteine hydrochloride, DL-
serine, DL-threonine, dicyclopentadiene, sodium lump in oil, and iodine were 
purchased from Aldrich or Acros and used as received.  DMF, acetone, 
acetonitrile, ether, isopropanol and methanol were purchased from Acros and 
used as received, or purified using standard methods. Deionized water with 
																																																								
2	S. G. Suman, J. M. Gretarsdottir, P. E. Penwell, S. Björgvinsdóttir, J. P. 
Gunnarsson, S. Frostason, E. Skulason, A. Garden, Björnsson, R., manuscript  in 
preparation.	
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conductivity of 18 mΩ-1cm-1 or less was used without further treatment. The 
complexes, [Mo2O2S2(DMF)6](I)2, 24 (Et4N)2[Mo2O2S8]; (Et4N)2(1), 25 
(Et4N)[CpMo2O2S4];  (Et4N)(2), 24 [Mo2O2S4(DMF)3]; (3),25 and 
Na2[Mo2O2S2(C3H7NO2S)2].2H2O, Na2(4),26 were synthesized according to 
published procedures. 
2.2. Physical Measurements: UV-Visible spectra and solubility 
measurements were recorded with Varian Cary 100 Bio spectrophotometer 
and Perkin Elmer Lambda 25 UV/Vis spectrophotometer at 22°C. Infrared 
spectra were recorded using a Smart Omni-Transmission Nicolet iS10 at 
21°C. 1H and 13C NMR spectra were recorded using a Bruker 400 Ultrashield 
NMR spectrometer. Mass spectra were recorded using a Bruker micrOTOF 
(Bruker autoflex smartbeam) mass spectrometer. Cell counting of cell 
suspensions was performed with a Bio-rad TC10TM Automated Cell Counter.  
2.3. Syntheses.  
K[Mo2O2S4(C3H6NO3)], K(5) To an acetone (50 mL) solution of (3) (0.50 g, 
0.87 mmol) was added a solution of tBuOK (97 mg, 0.86 mmol) and serine 
(91 mg, 0.89 mmol) in EtOH (20 mL).  The red solution was stirred 30 
minutes. The solvent was removed under reduced pressure and the residue 
treated with diethyl ether. An orange solid was collected by filtration and air-
dried. Yield: 0.28 g, 65%. 
IR(KBr, cm-1): 3417(m), 3216(m), 3126(m), 2945(w), 2891(w), 2853(w), 
1628 (vs), 1401(ms), 1344(m), 1105(m), 1023(m), 997(w), 935(s), 517(m), 
464(m). UV/visible (H2O): 282, 310(sh), 358(sh), 460(sh). 1H NMR (D2O): 
δ, ppm; 3.87(m, 1H), 3.99(m, 2H). 13C NMR{1H decoupled} (D2O): δ = 
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56.35, 60.13, 172.28. MS (ESI): M (KMo2O5S4NC3H6) 495.34 g/mol; -m/z 
found (calc.) = 459.7275(459.7242) [M-K+]-. 
[Mo2O2S2(C4H8NO3)2], (6) To an acetone (100 mL) solution of 
[Mo2O2S2(DMF)6](I)2  (0.50 g, 0.87 mmol) was added a solution of Na2CO3 
.10H2O (0.24 g, 0.84 mmol) and threonine (0.21 g, 1.7 mmol) in water (20 
mL).  The red-orange solution was stirred 30 minutes. The solvent was 
removed under reduced pressure. The residue treated with methylene chloride 
and ether, collected by filtration, and recrystallized from DMF/ether. A red 
orange solid was collected. Yield: 0.32 g, 62%. 
IR(KBr, cm-1): 3408(m), 3222(m), 3101(m), 2973(w), 2929(w), 1652 (vs), 
1366(ms), 1337(ms), 1136(m), 1105(m), 1001(w), 945(ms), 546(w), 465(w). 
UV/visible (H2O): 281, 302(sh), 362(sh), 447(sh). 1H NMR (D2O): d, ppm; 
1.62(m, 3H), 3.85(m, 1H), 4.41(m, 1H). 13C NMR{1H decoupled} (D2O): δ = 
19.20, 64.76, 72.77, 159.02. MS (ESI): M (Mo2O8S2N2C8H16) 524.26 g/mol; 
-m/z found (calc.) = 526.8383(526.8387) [M-H+]-. 
2.4. Water Solubility. The solubility of the compounds was determined by 
preparing a saturated solution of the respective compound in water, 
centrifuging and pipetting 100 µL of the solution and diluting to 5 or 10 mL 
and measuring the absorbance of the compound at its charge transfer peak 
maximum wavelength, taking care the absorbance is less than 1.0. The 
previously determined molar absorptivity constant, ε, was used to calculate 
the solution molar concentration M. The molecular weight was used to 
convert to g/L. The results are shown in table 2. 
2.5. Cell Division. Cell lines used were; MCF-7 (breast cancer), PT45 
(pancreatic cancer), HT29 (colon cancer). The MTT assay was used to 
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measure cell viability.27 The medium used was DMEM (1x) (Dulbecco's 
Modified Eagle Medium with [+] 4.5 g/L D-Glucose, [+] L-Glutamine, [-] 
Pyruvate in 10% Fetal Calf Serum). 
Three cell culture dishes (Thermo nuclon and Sarstedt) were incubated in a 
humidified system (37°C, 10% CO2); each containing one cell line along 
with medium. The medium was removed and the cells washed with a DPBS 
(1x) salt solution (Dulbecco's Phosphate Buffered Saline). TE solution 
(Trypsin/EDTA, 2 mL) was added to each cell culture dish and the dishes 
incubated in a humidified system (37°C, 10% CO2) until the cells were 
loose from the surface. DMEM (8 mL) was added to each plate and mixed 
well with the cells. The resulting cell suspensions were transferred to 50 mL 
reaction tubes. The samples were centrifuged (2 min, 300G) forming cell 
sediment in each tube. The supernatant was removed from the reaction 
tubes and fresh medium (10 mL) was subsequently added to each tube, and 
the cells re-suspended and thoroughly mixed. The cell density was obtained 
as cells/mL. After preparing all dilutions accordingly, four consecutive 
columns per compound were plated with 6000 cells/100 µL per well in a 96-
well plate.  
2.6. Treatment of Cells and Cell Viability Determination. Seven compounds 
were tested for toxicity on the three different cell lines. Stock solutions of 
each compound (10 mM) were prepared in either water or DMSO. The stock 
solutions were further diluted to working solutions with eight different 
concentrations for each compound. Cell viability was obtained for each 
compound after 24h, 48h and 72h. The 96-well plates were removed from the 
incubator and 50 µL of MTT solution (2.5 mg/mL MTT in DPBS (1x), sterile 
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filtered) were added to each well. The plates were then further incubated for 
2h during which the metabolized MTT formed purple formazan crystals 
proportional to cell viability per well. The supernatant was removed promptly 
and the crystals dissolved in 200 µL of DMSO. The absorption of each well 
was measured at 550 nm (background at 620 nm) and used to calculate IC50 
values of each compound. The IC50 values were only determined for the 72h 
time intervals, because decrease in cell viability was not observed until after 
72h. The data was worked up and IC50 values determined using GraphPad 
Prism. The results are presented in Table 1.  
2.7. Safe Dose Study in vivo. Male mice (C57bl/6, 8 week old, Taconic) were 
housed for one week prior to conducting the study. Compounds (Et4N)2(1), 
(3) and Na2(4) were dissolved in Dulbecco’s phosphate buffered saline at a 
dose concentrations of 0.5 mg/mL, 1.0 mg/mL, and 3.5 mg/mL respectively.  
Each compound was administered to three animals in 7.5 µL/Kg dose. Each 
animal was given four doses at one-hour intervals. Their well-being and 
weight was monitored for six days after.  The data is presented in Table 3. 
3. Results and Discussion 
3.1. Synthesis, Characterization and Water Solubility. The molybdenum 
sulfur complexes, 1- 6, are based on the molybdenum core structure shown in 
Figure 1. The core structure is a dianion that is capable of coordinating two to 
three ligands to each molybdenum center. The compounds were selected to 
represent bidentate monoanionic, tridentate dianionic, organometallic, and 
neutral monodentate ligands. Synthesis of these compounds was performed. 
The novel compounds K(5) and (6) were synthesized with amino acid ligands 
with the goal to increase the compound biocompatibility and to reduce 
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toxicity of the compounds in vivo as well as increase aqueous solubility as is 
desirable for catalytic drug development. Known compounds were included 
as they are well suited to demonstrate solubility and toxicity of alkali metal 
salts and for the purpose of analyzing properties for further studies.  
The synthesis of the known compounds (1-4) was performed according to 
published procedures.24,25,26 The novel compound K(5) was synthesized from 
(3) by displacement of the DMF ligands with deprotonated serine in 
acetone/ethanol mixture, and isolation of the compound as a red orange solid. 
Compound (6) was synthesized starting with the [Mo2O2S2(DMF)6](I)2 
complex and displacing all six DMF ligands with deprotonated threonine in 
acetone/water solvent mixture. The progress of the reactions was monitored 
using electronic spectroscopy. The reaction took place in aqueous solution 
according to the electronic spectroscopy, but eventually the synthesis was 
performed in organic solvents because initial efforts employing aqueous 
synthesis led to low isolated yields when precipitating out of water due to 
aqueous solubility of complexes K(5) and (6). Switching to organic solvents 
achieved 65% and 62% yields of the isolated K(5) and (6). The compounds 
are orange colored solids, and air stable. They were characterized using IR 
(infrared), NMR and mass spectroscopy. Infrared spectra of (Et4N)2(1), K(5), 
and (6) as KBr pellets are provided in the supplementary material, as well as 
UV-visible spectra of (3) and K(5) in water. The structures of the six 
compounds are shown in Figure 2.  
The compounds (1-6) all have the common core [Mo2O2S2]2+, but contain 
different ligands. They exhibit several characteristic features in the infrared 
spectra. The molybdenyl stretch is observed as a single stretch in the 
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symmetric compounds Na2(4) and (6) at 945 cm-1. This stretching frequency 
is similar as is observed for the molybdenyl in the Na2[Mo2O4(cys)2] 
compound 28  The carboxylate in Na2(4) is observed at unusually low 
wavenumber of 1590 cm-1 normally assigned to ionic non-coordinated 
cysteine.29 The cysteine coordination is tridentate, and the carboxylate is 
coordinated to the Mo-O(carboxylate) through an unusually long Mo-O 
bond, or 230 pm compared to 217 pm in the oxalato complex, 
Na[Mo2O4(C2O4)2].2H2O  where the carboxylate oxygen is also trans to the 
molybdenyl moiety.30,31 The coordination of the cysteine carboxylate to Mo 
is therefore weaker than in the oxalato compound and slightly sterically 
hindered. Threonine, as a monoanionic bidentate ligand in (6) shows this 
carboxylate stretch at higher wavenumber of 1626 cm-1 that is comparable to 
carboxylate stretches observed for molybdenum bound oxalates.32 In the 
asymmetric compounds (1, 2, 3, and 5), two molybdenyl stretches are 
observed with the second band at 935 cm-1. The spectroscopy of the known 
compounds has been discussed in detail along with their crystal structures 
elsewhere.24 The bridging sulfur is observed in all of the complexes (1-6) at 
474 cm-1. The terminal disulfide is characteristically observed in range of 517 
cm-1 to 521 cm-1. 
The electronic spectra exhibit an intense charge transfer band that peaks at 
around 300 nm (1-6). For the compounds with disulfide stretch, an additional 
weak transition is observed at 460 nm (1, 2, 3, 5). The mass spectra were 
obtained using electron ionization that provides the molecular ion minus a 
proton for the neutral complexes (3) and (6) while the molecular anion was 
obtained for the monoanions Et4N(2) and K(5). The dianions (Et4N)2(1) and 
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Na2(4) retain one cation and are observed as the complex anion plus one 
cation to form an overall monoanion. 
The compounds used for the study were selected based on three parameters: 
water solubility, estimated toxicity as high or low, and finally structure. 
Table 2 shows the water solubility for the least soluble compound, 
(Et4N)2(1), for (3), and for the most soluble compound Na2(4). The structures 
present variations in the choice of a cation and in ligand selection. For 
example, compound K(5) is highly soluble in water as the potassium salt, but 
is less soluble in water as the tetraethylammonium salt.3 
Tetraalkylammonium salts are considerably less soluble in water than the 
neutral compounds, while (Et4N)2(1)  only has water solubility of 1 g/L, and 
Na2(4) is very soluble with 136 g/L compared to NaCl solubility of 359 g/L 
in water.33  Solubility was observed as qualitatively larger for the alkali metal 
salts than for the neutral compounds. The monopotassium salt K(5) with 
serine ligand is less water soluble than the neutral bis-threonine complex (6), 
contrary to expectation. This lack of solubility may be explained by 
interaction of the hydroxylgroup of serine with neighboring molybdenum 
atoms. This hydroxylgroup is quite accessible since it does not serve as a 
donor group but it may interact with molybdenum in a second molecule and 
form extended structures. Such behavior is known for coordinated amino 
acids, where the amine group and C=O of the carboxylate of methionine from 
polymeric structures with first row transition metal ions with unsaturated 
coordination geometry.34  
																																																								
3	Infrared spectra of Et4N(5) is identical to K(5) except for vibrations originating 
from the Et4N+ cation. 
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Compounds (3) and (6) are both neutral but with very different ligand set. 
Interestingly, the polar DMF ligands in (3) are not displaced by water in 
aqueous solution, and the compound is quite stable at neutral pH. The 
combination of DMF and a disulfide ligand in (3) shows less solubility in 
water than (6) with two threonine ligands. Accordingly, K(5) is less soluble 
than compounds Na2(4) and (6), but more soluble than (3). The compounds 
were ranked according to aqueous solubility as Na2(4) > (6) > K(5) > (3) > 
(Et4N)(2) > (Et4N)2(1). These results are promising for continuing studies of 
how to increase solubility of the compounds further providing a foundation 
for future studies of the effects of a single anion with various cations. 
3.2. Cytotoxicity Studies. Ranking of compounds according to relative 
toxicity using in vitro approach has great value for guiding synthetic efforts 
for novel compounds with limited reported literature data. Cisplatin was used 
as a reference compound and, as is known, it is fairly toxic. Cancer cells were 
deemed suitable since they are already sensitized and therefore expected to 
show maximum sensitivity allowing us to rank the compounds according to 
their relative toxicity. The calculated IC50 values are shown in Table 1. 
The cytotoxicity assays were performed for three different cell lines. Cell 
viability was measured at 72h with the MTT method. MTT was shown 
recently to give false positive values for cytotoxicity values in molybdenum, 
and tungsten dichalcogenides, MoS2, WS2, and WSe2 due to reduction of 
MTT in the presence of the dichalcogenide.13 The dichalcogenides exhibit 
very low cytotoxicity in A549 normal epithelial cells.12  MTT background for 
the purpose of ranking our compounds according to relative cytotoxicity was 
not collected.  
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IC50 values were calculated using nonlinear regression and plotting the data 
as log(inhibitor) vs. response (three parameters). These values were used to 
rank the compounds according to relevant toxicity. As can be seen in Table 1, 
compounds (1 - 6) are not appreciably toxic compared to cisplatin. The data 
analysis method employs “% cell viability” as a function of log([c]) and 
prefers cell viability measurements close to the actual IC50 value to calculate 
accurate values. Since none of the compounds (1 – 6) showed less than 50% 
cell viability in the cell lines after 72h, it was necessary to employ an 
endpoint at zero viability and at 10 M concentration to sufficiently 
extrapolate the curve to correctly predict the IC50 values. Figure 3 shows the 
calculated IC50 values for the three cell lines together. The supplementary 
material has additionally Figures SI-3 - 5 that show graphically the calculated 
IC50 values for the different cell lines.  
Analysis of data obtained for (6) shows that without employing an endpoint 
of zero viability at 10 M concentration, the data is greatly misinterpreted. 
Data analysis of the cisplatin reference compound, where data is available 
well past the 50% cell viability point, shows that by using the zero viability at 
10 M end-point, the IC50 values calculated with this endpoint provide 
reasonable agreement. 
Tetraethylammonium salts were expected to show increased toxicity 
compared to alkali metal salts. Results and ranking of the compounds agrees 
with that expectation. Complexes (Et4N)2(1) and Et4N(2) are 
tetraethylammonium salts and clearly show higher cytotoxicity compared to 
the other complexes. Complexes Na2(4) and K(5) show least cytotoxicity 
comparatively, and complexes (3) and (6) are in between. Complex (3) has 
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three DMF ligands that are known to increase toxicity. The expected order of 
toxicity was (Et4N)2(1) >Et4N(2) > (3) > K(5) > Na2(4) = (6). The bis-
cysteine complex Na2(4) showed the least toxicity at a level that caused 
difficulty to determine an experimental end-point for the MCF-7 cell line and 
it was not possible for the HT29 cell line. The three cell lines showed 
preference towards different compounds and the ranking is therefore not 
identical for the three cell lines. Figure 4 shows the ranking of the 
compounds for PT45 cell line since it is representative for the compounds. 
Surprisingly, (6) exhibits more toxicity than expected and is comparable to 
compounds (3) and (5). The actual ranking is therefore: (Et4N)2(1) >Et4N(2) 
> (3) = K(5) = (6) > Na2(4). Preliminary studies using dose escalation method 
in vivo agree with the ranking observed for compounds (1), (3), and (4).  
3.3. In vivo Toxicity. Table 3 shows results from a preliminary safe dose 
study in vivo. (Et4N)2(1), (3), and Na2(4) were administered four times at one 
hour interval and the well-being of the animal monitored. None of the 
animals showed any sign of discomfort during the study. Their weight was 
monitored for a week afterwards and the maximum weight changes observed 
are reported with the dose information in table 3. The least soluble and the 
most soluble compounds were used for this study. They also represent the 
observed range of cytotoxicity and give an idea of expected future safe dose 
concentrations. 
Low solubility of (Et4N)2(1) prevented administration of sufficiently large 
dose to reach toxic levels. Compound (3) did show progressive weight loss 
for four days but the animals regained their initial weight after one week and 
did not show any discomfort. The solubility of compound (3) also prevented 
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administration of sufficiently large dose to induce toxicity at a dose of 7.5 
mg/Kg. Compound Na2(4) is highly soluble and we were not able to induce 
toxic effects in vivo  in this study. The animals did not show discomfort after 
four doses and showed very little weight fluctuations in the course of one 
week. 
Each dose of 26.3 mg/Kg administered of Na2(4) is much larger than an 
estimated dose of 30 mg/70 Kg person for an emergency treatment.4 This 
compound appears safe at much larger concentrations than is therapeutically 
expected and may have a large therapeutic index, currently a consideration 
for future studies. In comparison, tetrathiomolybdate also has a high 
therapeutic index where the effective dose of the compound is 25 mg/day for 
a 70 Kg person with a safe dose reported up to 1400 mg/day.35 Na2(4) safe 
dose appears well above potentially effective dose in our initial studies 
although more detailed studies are necessary to conclude any therapeutic 
indices for the compounds. 
4. Conclusion.  
The cytotoxicity of the six compounds in three cancer cell lines was 
employed to analyze structure-activity correlation of the effects of counter 
cation and ligands on cytotoxicity and aqueous solubility of the compounds. 
Our findings show the counter cation plays an important role in both 
solubility and cytotoxicity. The compounds were expected to be much less 
cytotoxic than cisplatin and promising for therapeutic applications requiring 
non-toxic compounds. The calculated IC50 values of compounds 1-6 are 
much higher than that of cisplatin as expected for non-toxic compounds. Our 
																																																								
4	Calculated based on unpublished data on catalytic activity of the compounds. 
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effort to increase water solubility and reduce cytotoxicity in parallel was 
successful. We showed the solubility improves both as a function of the 
counter cation selection as well as the ligands. Structure-activity correlation 
results are in good agreement with expected order of compound activity 
based on structure and salt selection. The core “Mo2O2S2” exhibits reduced 
cytotoxicity when combined with biocompatible ligands coordinated to the 
molybdenum atoms. Exchanging organic cations for alkali metal ions, and 
organosoluble ligands for amino acids both greatly reduce cytotoxicity and 
increase water solubility. The results for compounds 4 – 6 are encouraging 
for continuing studies of similar compounds, including further biological 
studies of these compounds. 
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Table 1. The table shows IC50 values (µM) obtained for complexes 1-6, and for 
cisplatin in three different cell lines after treating the cells for 72h and assayed 
with the MTT method.  
	
* Values for each measurement in the table are averages for four repeats. 





 Cell Line, IC50 values 
Compound 
no. 
MCF-7 PT45 HT29 
1 106 ± 32 34 ± 7 50 ± 3 
2 214 ± 35 64 ± 7 780 ± 259 
3 383 ± 45 118 ± 17 344 ± 10 
4 868 ± 319 189 ± 34 -* 
5 882 ± 350 117 ± 15 635 ± 98 
6 301 ± 126 95 ± 5 429 ± 219 
cisplatin 19.2 ± 1.93 5.73 ± 1.03 10.6 ± 2.28 
	
 











Table 3. The table shows the dose administered per compound, number of administrations and the maximum weight fluctuations recorded.  





Compound	 day	1	 day	2	 day	3	 day	4	 day	5	 day	6	 day	7	
(Et4N)2(1)	 3.8	 4	 0	 2	 3	 1	 -8	 2	 0	
[Mo2O2S4(DMF)3]	 7.5	 4	 -7	 -10	 -12	 -16	 -12	 -9	 -4	















IC50 (µM) determined for PT45 cells based on cell viability at 72 h. 
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SI1 and SI2: Graphs of data analysis for cisplatin and compound 6.  
SI3 to SI5: Graphs of results for calculated IC50 values for each cell line.  
SI6 to SI 8: Infrared spectra of (1), (5) and (6).  
SI9: UV-visible spectra of (3) and K(5). 
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Figure SI 1. Cisplatin in the three cell lines, data analysis using actual vs. using zero	






















Figure SI 2. Compound 6 in the three cell lines, data analysis using actual vs. using 


















Figure SI_3. The figure shows the calculated IC50 values for the compounds 1 - 6 and 





Figure SI_4. The figure shows the calculated IC50 values for the compounds 1- 6 and 
for cisplatin in the PT45 cell line. 
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Figure SI_5. The figure shows the calculated IC50 values for the compounds 1 -6 and 
for cisplatin in the HT29 cell line. It was not possible to determine the end-point for 
compound 4 due to high % cell viability at 72 hours.  
 
 
Figure SI_6.  Infrared spectrum of (Et4N)2(1) 
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Figure SI_7. Infrared spectrum of K(5) 
 
Figure SI_8. Infrared spectrum of (6) 
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